HLA-A and leukemia: However, as the range of suitably responsive tumors is still limited, we have proposed some new options, such as HLA-A*2402-restricted WT1-specific TCR [6] and HLA-A*0201-restricted Aurora kinase A (AURKA)-specific TCR [7], for the treatment of human leukemias.